Highlights from American Diabetes Association meeting include Lilly, AstraZeneca and Sanofi

7 June 2015

The American Diabetes Association (ADA) 75th annual meeting kicked off over the weekend in Boston with a plethora of news on investigational and already marketed diabetes treatments, among which were the following:

Lilly’s insulin peglispro

In newly released Phase III trial data, Eli Lilly (NYSE: LLY) and Company's (NYSE: LLY basal insulin peglispro (BIL) demonstrated statistically significantly lower hemoglobin A1c (HbA1c) compared to insulin glargine (Sanofi’s blockbuster Lantus) at 26 and 52 weeks in people with type 1 diabetes. Detailed results from the IMAGINE-1 and IMAGINE-3 clinical trials were presented at the ADA. People with type 1 diabetes in these trials were also taking mealtime insulin.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK